Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

Published

Journal Article (Review)

Highly active antiretroviral therapy (HAART) based on combinations of drugs that target key enzymes in the life-cycle of human immunodeficiency virus (HIV) has considerably reduced morbidity and mortality from HIV infection since its introduction in the mid-1990s. However, the growing problem of the emergence of HIV strains that are resistant not only to individual drugs, but to whole drug classes, means that agents with new mechanisms of action are needed. Here, we describe the discovery and development of enfuvirtide (Fuzeon), the first drug to inhibit the entry of HIV-1 into host cells.

Full Text

Duke Authors

Cited Authors

  • Matthews, T; Salgo, M; Greenberg, M; Chung, J; DeMasi, R; Bolognesi, D

Published Date

  • March 2004

Published In

Volume / Issue

  • 3 / 3

Start / End Page

  • 215 - 225

PubMed ID

  • 15031735

Pubmed Central ID

  • 15031735

International Standard Serial Number (ISSN)

  • 1474-1776

Digital Object Identifier (DOI)

  • 10.1038/nrd1331

Language

  • eng

Conference Location

  • England